



BSI Standards Publication

Biological evaluation of medical devices

Part 33: Guidance on tests to
evaluate genotoxicity — Supplement
to ISO 10993-3

National foreword

This Published Document is the UK implementation of ISO/TR 10993-33:2015.

The UK participation in its preparation was entrusted to Technical Committee CH/194, Biological evaluation of medical devices.

A list of organizations represented on this committee can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

© The British Standards Institution 2015.

Published by BSI Standards Limited 2015

ISBN 978 0 580 84781 3

ICS 11.100.20

Compliance with a British Standard cannot confer immunity from legal obligations.

This Published Document was published under the authority of the Standards Policy and Strategy Committee on 21 March 2015.

Amendments/corrigenda issued since publication

Date	Text affected
------	---------------

TECHNICAL
REPORT

ISO/TR
10993-33

First edition
2015-03-01

**Biological evaluation of medical
devices —**

**Part 33:
Guidance on tests to evaluate
genotoxicity — Supplement to ISO
10993-3**

Évaluation biologique des dispositifs médicaux —

*Partie 33: Directives sur les essais pour évaluer la génotoxicité —
Supplément à l'ISO 10993-3*



Reference number
ISO/TR 10993-33:2015(E)

© ISO 2015



COPYRIGHT PROTECTED DOCUMENT

© ISO 2015

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

Contents

Page

Foreword.....	vi
Introduction.....	viii
1 Scope.....	1
2 Selection of tests.....	1
3 Recommended tests.....	1
4 Use of <i>in vitro</i> tests to detect genotoxicity.....	2
5 Use of <i>in vivo</i> tests to detect genotoxicity.....	2
6 Bacterial reverse mutation assay.....	3
6.1 General.....	3
6.2 Preparations.....	3
6.2.1 Bacteria.....	3
6.2.2 Medium.....	4
6.2.3 Metabolic activation.....	4
6.2.4 Test sample preparation.....	4
6.3 Test conditions.....	4
6.3.1 Solvents.....	4
6.3.2 Exposure concentrations.....	5
6.3.3 Controls.....	6
6.4 Procedure.....	7
6.4.1 Treatment with test sample.....	7
6.4.2 Incubation.....	7
6.4.3 Data collection.....	7
6.5 Data and reporting.....	8
6.5.1 Treatment of results.....	8
6.5.2 Evaluation and interpretation of results.....	8
6.5.3 Criteria for a valid test.....	8
6.5.4 Test report.....	9
7 <i>In vitro</i> mammalian chromosome aberration test.....	11
7.1 General.....	11
7.2 Preparations.....	11
7.2.1 Cells.....	11
7.2.2 Media and culture conditions.....	11
7.2.3 Preparation of cultures.....	11
7.2.4 Metabolic activation.....	11
7.2.5 Test sample preparation.....	12
7.3 Test conditions.....	12
7.3.1 Solvents.....	12
7.3.2 Exposure concentrations.....	12
7.3.3 Controls.....	13
7.4 Procedure.....	14
7.4.1 Treatment with test sample or extract and harvest time.....	14
7.4.2 Chromosome preparation.....	14
7.4.3 Analysis.....	14
7.5 Data and reporting.....	15
7.5.1 Treatment of results.....	15
7.5.2 Evaluation and interpretation of results.....	15
7.5.3 Test report.....	15

Contents

Page

8	<i>In vitro</i> mammalian micronucleus test	17
8.1	General	17
8.2	Preparations	18
8.2.1	Cells	18
8.2.2	Media and culture conditions	18
8.2.3	Preparation of cultures	18
8.2.4	Metabolic activation	18
8.2.5	Use of cytoB as a cytokinesis blocker	18
8.2.6	Test sample preparation	19
8.3	Test conditions	19
8.3.1	Solvents	19
8.3.2	Exposure concentrations	19
8.3.3	Controls	20
8.4	Procedure	21
8.4.1	Treatment with test sample or extract and harvest time	21
8.4.2	Cell harvest and slide preparation	21
8.4.3	Analysis	22
8.5	Data and reporting	22
8.5.1	Treatment of results	22
8.5.2	Evaluation and interpretation of results	22
8.5.3	Test report	23
9	<i>In vitro</i> mammalian cell gene mutation test using mouse lymphoma (L5178Y) cells	25
9.1	General	25
9.2	Preparations	25
9.2.1	Cells	25
9.2.2	Media and culture conditions	25
9.2.3	Preparation of cultures	25
9.2.4	Metabolic activation	25
9.2.5	Test sample preparations	26
9.3	Test conditions	26
9.3.1	Solvent/vehicle	26
9.3.2	Exposure concentrations	26
9.3.3	Controls	27
9.4	Procedure	28
9.4.1	General	28
9.4.2	Treatment with test sample	29
9.4.3	Measurement of survival, viability and mutant frequency	29
9.5	Data and reporting	29
9.5.1	Treatment of results	29
9.5.2	Evaluation and interpretation of results	30

Contents

Page

10	<i>In vivo</i> mammalian erythrocyte micronucleus test	32
10.1	General	32
10.2	Preparations	33
10.2.1	Selection of animal species	33
10.2.2	Housing and feeding conditions	33
10.2.3	Preparation of the animals	33
10.2.4	Test sample preparation	33
10.3	Test conditions	34
10.3.1	Solvent/vehicle	34
10.3.2	Controls	34
10.4	Procedure	34
10.4.1	Number and sex of animals	34
10.4.2	Treatment schedule	34
10.4.3	Limit test	35
10.4.4	Dose levels	35
10.4.5	Routes of administration and doses levels	36
10.4.6	Bone marrow/blood preparation	36
10.4.7	Analysis	36
10.5	Data and reporting	37
10.5.1	Evaluation of results	37
10.5.2	Evaluation and interpretation of results	37
10.5.3	Test report	37
11	Chromosome aberration test (<i>in vivo</i>)	39
11.1	General	39
11.2	Preparations	39
11.2.1	Selection of animal species	39
11.2.2	Housing and feeding conditions	39
11.2.3	Preparation of the animals	39
11.2.4	Test sample preparation	39
11.3	Test conditions	40
11.3.1	Solvent/vehicle	40
11.3.2	Controls	40
11.4	Procedure	40
11.4.1	Number and sex of animals	40
11.4.2	Treatment schedule	40
11.4.3	Dose levels	41
11.4.4	Limit test	41
11.4.5	Dose levels and routes of exposure	41
11.4.6	Bone marrow collection and preparation of slides	42
11.4.7	Analysis of Metaphase Cells	42
11.5	Data and reporting	42
11.5.1	Treatment of results	42
11.5.2	Evaluation and interpretation of results	42
11.5.3	Test report	43
	Bibliography	45

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the WTO principles in the Technical Barriers to Trade (TBT), see the following URL: [Foreword — Supplementary information](#).

The committee responsible for this document is ISO/TC 104, *Biological and clinical evaluation of medical devices*.

ISO 10993 consists of the following parts, under the general title *Biological evaluation of medical devices*:

- Part 1: Evaluation and testing within a risk management process
- Part 2: Animal welfare requirements
- Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity
- Part 4: Selection of tests for interactions with blood
- Part 5: Tests for in vitro cytotoxicity
- Part 6: Tests for local effects after implantation
- Part 7: Ethylene oxide sterilization residuals
- Part 9: Framework for identification and quantification of potential degradation products
- Part 10: Tests for irritation and delayed-type hypersensitivity
- Part 11: Tests for systemic toxicity
- Part 12: Sample preparation and reference materials
- Part 13: Identification and quantification of degradation products from polymeric medical devices
- Part 14: Identification and quantification of degradation products from ceramics
- Part 15: Identification and quantification of degradation products from metals and alloys
- Part 16: Toxicokinetic study design for degradation products and leachables
- Part 17: Establishment of allowable limits for leachable substances

- *Part 18: Chemical characterization of materials*
- *Part 19: Physico-chemical, morphological and topographical characterization of materials (Technical specification)*
- *Part 20: Principles and methods for immunotoxicology testing of medical devices (Technical specification)*
- *Part 33: Guidance on tests to evaluate genotoxicity - Supplement to ISO 10993-3 (Technical Report)*

Currently in preview, click buy full version

Introduction

Genotoxicity tests are designed to detect compounds which induce genetic damage directly or indirectly by various mechanisms. These tests should enable hazard identification with respect to genetic damages. Expression of gene mutations, large scale chromosomal damage, recombination, and numerical changes are generally considered to be essential for heritable effects and the multi-step carcinogenesis. A positive genotoxicity test provides an indication that further testing can be warranted to determine the carcinogenic potential of the compound. Because the relationship between exposure to particular chemicals and carcinogenesis is established for man, while a similar relationship has been difficult to prove for heritable diseases, genotoxicity tests have been used mainly for the prediction of carcinogenicity. Nevertheless, because germ line mutations are clearly associated with human disease, the suspicion that a compound can induce heritable effects is considered to be just as serious as the suspicion that a compound can induce cancer. In addition, the outcome of such tests can be valuable for the interpretation of carcinogenicity studies.

Biological evaluation of medical devices —

Part 33:

Guidance on tests to evaluate genotoxicity — Supplement to ISO 10993-3

1 Scope

There are differences between the views of regulatory bodies on the subject of genotoxicity testing. The purpose of this Technical Report is to provide background information to facilitate the selection of tests and guidance on the performance of tests.

2 Selection of tests

Since chemicals can induce genetic damage by different mechanisms, a battery of tests sensitive to different types of genetic damage are thought to provide the best assurance for detecting genotoxic hazard. The tests selected usually include tests to detect point mutations and tests to detect chromosomal aberrations. Both bacterial cells and cultured mammalian cells are used to detect genotoxic agents. *in vivo* tests are sometimes incorporated into these test batteries. These tests are sometimes included in the initial test battery or are used to clarify results from *in vitro* tests, see Reference [13].

3 Recommended tests

Although there are some variations in details, the same genotoxicity tests are commonly recommended by most regulatory agencies. The following are commonly recommended tests:

- bacterial reverse mutation test (see OECD 471[1] and [Clause 6](#));
- *in vitro* mammalian chromosome aberration test (see OECD 473[2] and [Clause 7](#));
- *in vitro* mammalian micronucleus test (see OECD 487[6] and [Clause 8](#));
- *in vitro* mammalian cell gene mutation test using mouse lymphoma (L5178Y) cells (see OECD 475[4] and [Clause 9](#));
- *in vivo* mammalian erythrocyte micronucleus test (see OECD 474[3] and [Clause 10](#));
- *in vivo* chromosome aberration test (see OECD 475[5] and [Clause 11](#)).

For medical devices, a battery of tests is commonly used for genotoxicity evaluations. The general strategy identified in ISO 10993-3 is as follows:

- a) test for gene mutations in bacteria. Bacterial Reverse Mutation Assay, OECD 471[1] technically modified for medical devices to allow, for example, testing with extracts from devices (see [Clause 6](#));
and either
- b) an *in vitro* test with cytogenetic evaluation of chromosomal damage with mammalian cells, Chromosome aberration test, OECD 473[2] technically modified for medical devices (see [Clause 7](#)), or
- c) an *in vitro* mouse lymphoma tk assay, OECD 476[5] technically modified for medical devices (see [Clause 8](#)) including detection of small (slow growing) and large colonies, or